A Bioequivalence Study of a Randomized, Open-label, Single Dose, Two-way Crossover Design With Two-period, Two-treatment and Two-sequence of Ticagrelor Tablets 90 mg Relative to Originator in Healthy Thai Volunteers Under Fasting Condition.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 36
- 主要终点
- Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)
研究概览
简要总结
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.
详细描述
Title A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Ticagrelor Tablets 90 mg relative to Originator Ticagrelor Tablets 90 mg in healthy Thai volunteers under fasting condition.
Objectives The primary objective is to assess the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai volunteers.
Study Design Randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.
Sample Size 36 Healthy Human Thai subjects. Two extra subjects if available, may be checked-in on the day of check in of period-I to compensate for any dropout prior to dosing of period-I. These subjects will be dosed if there are dropouts prior to dosing in period-I. If there are no dropouts, these subjects will be checked-out without being dosed after completion of dosing in period-I.
Drug-Product Test-Product: Ticagrelor Tablets 90 mg Reference-product: BRILINTATM (Film-Coated Tablets) 90 mg Manufactured by: AstraZeneca AB, Sweden
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
盲法说明
The randomization schedule will be blinded to the analysts until the end of the study.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willingness to provide written informed consent prior to participate in the study.
- •Healthy Thai subjects are between 18 to 55 years of age.
- •The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m
- •Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 10 mL of blood for monitoring subjects' safety after the completion of the study.
- •Negative urine pregnancy test for women and no breast-feeding.
- •Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
排除标准
- •History or evidence of allergy or hypersensitivity to Ticagrelor or any related drugs or any of the excipients of this product.
- •Subject with B.P. is Systolic B.P < 90, ≥140 mm/Hg, Diastolic B.P < 60, ≥90 mm/Hg, pulse rate > 100 beats per minute.
- •Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).*
- •Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- •PT (Prothrombin time) and aPTT (Activated partial thromboplastin time) are above normal range.*
- •Positive of hepatitis B or C virus.
- •Have more than one abnormal EKG, which is considered as clinically significant.*
- •History or evidence of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope.
- •History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension or glaucoma.
- •History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •History of psychiatric disorder.
- •History or presence of major active bleeding or abnormal bleeding due to hemorrhoids, epistaxis, gastrointestinal ulcer or other symptoms in past 1 month before the study drug administration and until the completion of the study.
- •History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •History of grapefruit, pomelo or grapefruit products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
- •Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication or Inducer/inhibitor CYP enzymes within 28 days prior to receiving the first dose of study medicine.
- •History of difficulty in accessibility of veins in left and right arm.
- •Blood donation (one unit or 450 mL) within the past 3 months before the study.
- •Participation in any clinical study within the past 3 months before the study.
- •Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
- •(* Depend on decision of principal investigator and/or clinical investigator)
研究组 & 干预措施
Sequence 1-Ticagrelor test product and then reference product
Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
干预措施: Ticagrelor-Test product (Drug)
Sequence 2-Ticagrelor reference product and then test product
Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Ticagrelor Tablets 90 mg test product, treatment 2= Ticagrelor Tablets 90 mg reference product.
干预措施: Ticagrelor-Reference product (Drug)
结局指标
主要结局
Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)
时间窗: Blood samples will be coll pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
Maximal measured plasma concentration (Cmax)
时间窗: Blood samples will be coll pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
pre-dose and at 0.333, 0.667, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000, 3.333, 3.667, 4.000, 4.500, 5.000, 6.000, 8.000, 10.000, 14.000, 20.000, 24.000, 36.000 and 48.000 hours after study drug administration
次要结局
- Number of subjects with adverse events(Approximately the day 14 after the last visit)
研究者
Sasitorn Kittivoravitkul
Principal Investigator
Bio-innova Co., Ltd